Etanercept biosimilar - LG Chem

Drug Profile

Etanercept biosimilar - LG Chem

Alternative Names: LBEC-0101; TNFcept

Latest Information Update: 11 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LG Life Sciences
  • Developer LG Chem; Mochida Pharmaceutical
  • Class Antipsoriatics; Antirheumatics; Disease-modifying antirheumatics; Recombinant fusion proteins
  • Mechanism of Action Immunosuppressants; Tumour necrosis factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Rheumatoid arthritis

Most Recent Events

  • 16 Jun 2018 LG Life Sciences completes a phase III extension trial in Rheumatoid arthritis (Adjunctive treatment) in South Korea (SC)
  • 30 May 2018 Launched for Rheumatoid arthritis (Adjunctive treatment) in Japan (SC) - First global Launch
  • 19 Jan 2018 Registered for Rheumatoid arthritis (Adjunctive treatment) in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top